HMGB1–Platelet Interactions: Mechanisms and Targeted Therapy Strategies
Thrombosis and Haemostasis · 01.04.2026 · 126 (04) · 346-358
DOI: 10.1055/a-2622-0074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2026. Verfasst von Xiyuan Fang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, People's Republ…. Hauptthemen laut MEDLINE: HMGB1 Protein, Blood Platelets. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Project of China.
Abstract (Originalsprache)
Platelets serve not only as crucial hemostatic components but also as pivotal regulators of inflammatory responses, capable of interacting with diverse cell types and secreting abundant extracellular factors. Accumulating evidence demonstrates that high mobility group box 1 (HMGB1), a DNA-binding protein and critical inflammatory mediator, plays multifaceted roles in disease progression, with platelets being one cellular source of circulating HMGB1. Under pathological conditions, platelets release HMGB1 into the extracellular matrix, establishing bidirectional communication between platelets and other immune cells. Moreover, HMGB1 reciprocally activates platelets through Toll-like receptors (TLRs) and receptor for advanced glycation end-products (RAGE), facilitating platelet activation and subsequent release of regulatory factors that drive inflammation-associated pathological thrombosis. In this review, we systematically characterize the HMGB1–platelet axis and elucidate its context-dependent roles in specific disease states. The mechanistic interplay between HMGB1 signaling and platelet pathophysiology is discussed, particularly its implications for disease progression. Furthermore, we critically evaluate therapeutic strategies targeting HMGB1 developed over the past decade, while proposing future directions for dual-target interventions that simultaneously modulate HMGB1 and platelet activity to combat inflammation-driven thrombotic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Wuhan, People's Republic of China.
- Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
- Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei, People's Republic of China.
- Department of Stomatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
- School of Stomatology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Project of China
Zitieren
APA
Fang, X., Zhou, X., Zhou, X., Cheng, Z., & Hu, Y. (2026). HMGB1–Platelet Interactions: Mechanisms and Targeted Therapy Strategies. Thrombosis and Haemostasis, 126(04), 346-358. https://doi.org/10.1055/a-2622-0074
Vancouver
Fang X, Zhou X, Zhou X, Cheng Z, Hu Y. HMGB1–Platelet Interactions: Mechanisms and Targeted Therapy Strategies. Thrombosis and Haemostasis. 2026;126(04):346-358. doi:10.1055/a-2622-0074
BibTeX
@article{Fang2026,
author = {Fang, Xiyuan and Zhou, Xianghui and Zhou, Xin and Cheng, Zhipeng and Hu, Yu},
title = {HMGB1–Platelet Interactions: Mechanisms and Targeted Therapy Strategies},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {04},
pages = {346--358},
doi = {10.1055/a-2622-0074}
}
EUVIMED